Table 2.
Baseline medication of the study population with a comparison between the Netherlands and Belgium
| Medication | NL & BE N = 967 |
The Netherlands N = 648 |
Belgium N = 319 |
NL vs BE | |||
|---|---|---|---|---|---|---|---|
| N (%) | Missing | N (%) | Missing | N (%) | Missing | p-value | |
| VKA | 453 (46.9) | 2 | 344 (53.2) | 1 | 109 (34.3) | 1 | < 0.001 |
| Rivaroxaban | 188 (19.5) | 2 | 124 (19.1) | 1 | 64 (20.1) | 1 | 0.723 |
| Dabigatran | 99 (10.3) | 2 | 63 (9.7) | 1 | 36 (11.3) | 1 | 0.446 |
| Apixaban | 130 (13.5) | 2 | 57 (8.8) | 1 | 73 (23.0) | 1 | < 0.001 |
| Edoxaban | 5 (0.5) | 2 | 5 (0.8) | 1 | – | 1 | 0.178 |
| LMWH | 13 (1.3) | 2 | 1 (0.2) | 1 | 12 (3.8) | 1 | < 0.001 |
| Any anticoagulation drug | 887 (91.9) | 2 | 593 (91.7) | 1 | 294 (92.5) | 1 | 0.669 |
| ASA | 101 (10.5) | 2 | 40 (6.2) | 1 | 61 (19.2) | 1 | < 0.001 |
| Clopidogrel | 29 (3.0) | 2 | 19 (2.9) | 1 | 10 (3.1) | 1 | 0.859 |
| Ticagrelor | 4 (0.4) | 2 | 4 (0.6) | 1 | – | 1 | 0.309 |
| Dipyridamole | 2 (0.2) | 2 | 1 (0.2) | 1 | 1 (0.3) | 1 | 0.551 |
| Sotalol | 141 (14.6) | 2 | 111 (17.2) | 1 | 30 (9.4) | 1 | 0.001 |
| – Mean ± SD dose per day in mg | 155 ± 74 | 149 ± 73 | 176 ± 75 | 0.056 | |||
| Amiodaron | 128 (13.3) | 3 | 38 (5.9) | 2 | 90 (28.3) | 1 | < 0.001 |
| – Mean ± SD dose per day in mg | 232 ± 105 | 208 ± 78 | 241 ± 115 | 0.052 | |||
| Flecainide | 80 (8.3) | 2 | 53 (8.2) | 1 | 27 (8.5) | 1 | 0.874 |
| – Mean ± SD dose per day in mg | 151 ± 57 | 142 ± 54 | 169 ± 61 | 0.078 | |||
| Propafenone | 4 (0.4) | 2 | – | 1 | 4 (1.3) | 1 | 0.012 |
| Disopyramide | 3 (0.3) | 2 | 2 (0.3) | 1 | 1 (0.3) | 1 | 0.999 |
| Any anti-arrhythmic drug | 354 (36.7) | 2 | 203 (31.4) | 1 | 151 (47.5) | 1 | < 0.001 |
| Beta blocker | 541 (56.1) | 3 | 367 (56.8) | 2 | 174 (54.7) | 1 | 0.538 |
| CCB | 171 (17.7) | 2 | 117 (18.1) | 1 | 54 (17.0) | 1 | 0.673 |
| Digoxin | 141 (14.6) | 2 | 126 (19.5) | 1 | 15 (4.7) | 1 | < 0.001 |
| Any rate control drug | 653 (67.7) | 2 | 448 (69.2) | 1 | 205 (64.5) | 1 | 0.136 |
| ACE inhibitor | 307 (31.8) | 2 | 185 (28.6) | 1 | 122 (38.4) | 1 | 0.002 |
| Angiotensin receptor blocker | 196 (20.3) | 2 | 132 (20.4) | 1 | 64 (20.1) | 1 | 0.920 |
| Aliskiren | 6 (0.6%) | 2 | – | 1 | 6 (1.9) | 1 | 0.001 |
| Aldosterone blockers | 65 (6.7) | 2 | 35 (5.4) | 1 | 30 (9.4) | 1 | 0.019 |
| Any RAAS inhibiting drug | 529 (54.8) | 2 | 327 (50.5) | 1 | 202 (63.5) | 1 | < 0.001 |
| Diuretics | 335 (34.7) | 2 | 221 (34.2) | 1 | 114 (35.8) | 1 | 0.604 |
| Non-DHP CCB | 58 (6.0) | 2 | 46 (7.1) | 1 | 12 (3.8) | 1 | 0.040 |
| Statin | 409 (42.4) | 2 | 260 (40.2) | 1 | 149 (46.9) | 1 | 0.049 |
| Oral anti-diabetics | 133 (13.8) | 2 | 73 (11.3) | 1 | 60 (18.9) | 1 | 0.001 |
| Insulin | 35 (3.6) | 2 | 24 (3.7) | 1 | 11 (3.5) | 1 | 0.845 |
| Thyroid hormones | 64 (6.6) | 2 | 19 (2.9) | 1 | 45 (14.2) | 1 | < 0.001 |
| Thyroid-suppressing drugs | 10 (1.0) | 2 | 7 (1.1) | 1 | 3 (0.9) | 1 | 0.842 |
| Proton pump inhibitors | 275 (28.5) | 2 | 201 (31.1) | 1 | 74 (23.3) | 1 | 0.012 |
ACE angiotensin-converting enzyme, ASA acetylsalicylic acid, CCB calcium channel blocker, DHP dihydropyridine, LMWH low molecular weight heparins, RAAS renin-angiotensin-aldosterone system, SD standard deviation, VKA vitamin K antagonist